Lanadelumab significantly reduces HAE attacks in long-term use: Study
A real-world study published in the International Archives of Allergy and Immunology found that 3 years of lanadelumab treatment led to a substantial decrease in hereditary angioedema (HAE) attacks. The proportion of patients experiencing monthly attacks dropped from 54% before treatment to just 9.8% after long-term use.
Hereditary angioedema is typified by recurring, erratic episodes of body swelling which affects both adults and children, with an estimated frequency of 1:50,000. The kallikrein-kinin cascade is dysregulated as a result of either a deficiency (HAE-C1INH-Type1) or dysfunction (HAEC1INH-Type2) of the C1 esterase inhibitor, which causes the clinical manifestations of HAE. Clinically, HAE attacks show up as nonpitting, nonpruritic edema that mostly affects the upper airway, abdominal organs, and subcutaneous tissue.
A monoclonal antibody called lanadelumab, which blocks plasma kallikrein, is authorized for the long-term prevention of HAE attacks in patients two years of age or older in the US and Europe, and 12 years of age or older in several other countries. Lanadelumab was approved for long-term prophylaxis in individuals with HAE based on clinical studies; yet, there is a lack of empirical evidence about the long-term usage of lanadelumab in HAE patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.